PT1613350E - Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa - Google Patents
Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa Download PDFInfo
- Publication number
- PT1613350E PT1613350E PT04759142T PT04759142T PT1613350E PT 1613350 E PT1613350 E PT 1613350E PT 04759142 T PT04759142 T PT 04759142T PT 04759142 T PT04759142 T PT 04759142T PT 1613350 E PT1613350 E PT 1613350E
- Authority
- PT
- Portugal
- Prior art keywords
- tnf
- therapy
- autoimmune disease
- patient
- inadequate response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46148103P | 2003-04-09 | 2003-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1613350E true PT1613350E (pt) | 2009-06-24 |
Family
ID=33299824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT04759142T PT1613350E (pt) | 2003-04-09 | 2004-04-06 | Terapia de doença auto-imune num paciente com uma resposta inadequada a um inibidor de tnf-alfa |
Country Status (32)
Country | Link |
---|---|
US (4) | US20040202658A1 (pt) |
EP (2) | EP1613350B1 (pt) |
JP (3) | JP2006522811A (pt) |
KR (2) | KR101092171B1 (pt) |
CN (2) | CN101371924A (pt) |
AT (1) | ATE425766T1 (pt) |
AU (1) | AU2004229376B2 (pt) |
BR (1) | BRPI0409534A (pt) |
CA (1) | CA2519870A1 (pt) |
CR (1) | CR8033A (pt) |
CY (1) | CY1109127T1 (pt) |
DE (1) | DE602004020061D1 (pt) |
DK (1) | DK1613350T3 (pt) |
EC (1) | ECSP056082A (pt) |
ES (1) | ES2322267T3 (pt) |
HK (1) | HK1086480A1 (pt) |
HR (2) | HRP20050940A2 (pt) |
IL (2) | IL171038A (pt) |
MA (1) | MA27838A1 (pt) |
ME (1) | ME00426B (pt) |
MX (1) | MXPA05010778A (pt) |
NO (1) | NO20055253L (pt) |
NZ (2) | NZ587776A (pt) |
PL (1) | PL1613350T3 (pt) |
PT (1) | PT1613350E (pt) |
RS (1) | RS51686B (pt) |
RU (1) | RU2358762C9 (pt) |
SI (1) | SI1613350T1 (pt) |
TN (1) | TNSN05234A1 (pt) |
UA (2) | UA99933C2 (pt) |
WO (1) | WO2004091657A2 (pt) |
ZA (1) | ZA200507805B (pt) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1642596A3 (en) | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
PL201086B1 (pl) * | 1999-07-12 | 2009-03-31 | Genentech Inc | Zastosowanie przeciwciał wiążących się z antygenem CD20 |
AU2003215365A1 (en) | 2002-02-21 | 2003-09-09 | Duke University | Treatment methods using anti-cd22 antibodies |
US20090217404A1 (en) * | 2002-09-27 | 2009-08-27 | Lowe Scott W | Cell-based RNA interference and related methods and compositions |
BRPI0316779B1 (pt) * | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
WO2004074445A2 (en) * | 2003-02-17 | 2004-09-02 | Cold Spring Harbor Laboratory | Model for studying the role of genes in tumor resistance to chemotherapy |
US20090186839A1 (en) * | 2003-02-17 | 2009-07-23 | Cold Spring Harbor Laboratory | Model for studying the role of genes in chemoresistance |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
JP2006522811A (ja) | 2003-04-09 | 2006-10-05 | ジェネンテック・インコーポレーテッド | TNFαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法 |
EP1626993B1 (en) * | 2003-05-09 | 2015-03-11 | Duke University | Cd20-specific antibodies and methods of employing same |
AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2005023302A2 (en) * | 2003-08-29 | 2005-03-17 | Genentech, Inc. | Anti-cd20 therapy of ocular disorders |
SI2380911T1 (en) * | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
BRPI0509412A (pt) * | 2004-04-16 | 2007-09-04 | Genentech Inc | método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado |
EP3130349A1 (en) * | 2004-06-04 | 2017-02-15 | Genentech, Inc. | Method for treating multiple sclerosis |
SV2006002131A (es) * | 2004-06-04 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento de lupus |
WO2006012508A2 (en) * | 2004-07-22 | 2006-02-02 | Genentech, Inc. | Method of treating sjögren's syndrome |
EP1776384B1 (en) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Variant fc regions |
CN101087807A (zh) * | 2004-10-05 | 2007-12-12 | 健泰科生物技术公司 | 治疗血管炎的方法 |
US8137907B2 (en) * | 2005-01-03 | 2012-03-20 | Cold Spring Harbor Laboratory | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof |
ZA200705459B (en) * | 2005-01-13 | 2008-09-25 | Genentech Inc | Treatment method |
US8444973B2 (en) | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
AU2006214121B9 (en) * | 2005-02-15 | 2013-02-14 | Duke University | Anti-CD19 antibodies and uses in oncology |
CN101218256B (zh) * | 2005-03-23 | 2017-04-19 | 根马布股份公司 | 用于治疗多发性骨髓瘤的cd38抗体 |
AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
EP2221316A1 (en) * | 2005-05-05 | 2010-08-25 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
WO2006127517A2 (en) * | 2005-05-20 | 2006-11-30 | Genentech, Inc. | Pretreatment of a biological sample from an autoimmune disease subject |
CA2610265A1 (en) * | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methods for producing micrornas |
WO2006133450A2 (en) * | 2005-06-08 | 2006-12-14 | Duke University | Anti-cd19 antibody therapy for the transplantation |
JP2009508470A (ja) * | 2005-07-21 | 2009-03-05 | アボット・ラボラトリーズ | Sorf構築物並びにポリタンパク質、プロタンパク質及びタンパク質分解による方法を含む複数の遺伝子発現 |
US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
MY149159A (en) * | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
JP2009532336A (ja) | 2006-03-06 | 2009-09-10 | メディミューン,エルエルシー | ヒト化抗cd22抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用 |
EP1999148B8 (en) | 2006-03-06 | 2014-03-05 | Medlmmune, LLC | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2815768A3 (en) * | 2006-04-05 | 2015-01-14 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
IL282783B2 (en) | 2006-05-18 | 2023-09-01 | Caris Mpi Inc | A system and method for determining a personalized medical intervention for a disease stage |
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
CA2662340C (en) * | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US8420330B2 (en) * | 2011-07-15 | 2013-04-16 | Myra A. Lipes | Diagnosis and treatment of cardiac troponin 1 (cTn1) autoantibody-mediated heart disease |
GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
WO2009014263A1 (ja) * | 2007-07-26 | 2009-01-29 | Osaka University | インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤 |
DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
MX2010010028A (es) * | 2008-03-13 | 2011-08-17 | Biotest Ag | Agente para tratar enfermedad. |
SG190627A1 (en) * | 2008-03-13 | 2013-06-28 | Biotest Ag | Agent for treating disease |
EP2262838B1 (en) * | 2008-03-13 | 2016-04-13 | Biotest AG | Agent for treating disease |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
DK2341937T3 (en) * | 2008-09-29 | 2015-02-09 | Biotest Ag | Composition for the treatment of a disease |
EP3075864A1 (en) * | 2008-10-14 | 2016-10-05 | Caris MPI, Inc. | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type |
AU2009313296B2 (en) * | 2008-11-07 | 2015-07-23 | National Jewish Health | Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related B cells ("ABCs") |
BRPI0921043A2 (pt) * | 2008-11-12 | 2018-08-07 | Caris Life Sciences Luxembourg Holdings | métodos e sistemas para usar exossomas para determinar fenótipos |
RU2011124527A (ru) * | 2008-11-17 | 2012-12-27 | Дженентек, Инк. | Способ и композиция для уменьшения агрегации макромолекулы в физиологических условиях |
PE20120169A1 (es) * | 2008-11-17 | 2012-02-29 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US20110275791A1 (en) * | 2009-01-06 | 2011-11-10 | Ziad Mallat | A B Cell Depleting Agent for the Treatment of Atherosclerosis |
JP5246709B2 (ja) * | 2009-06-09 | 2013-07-24 | 独立行政法人医薬基盤研究所 | 自己免疫疾患検査用バイオマーカー及び検査方法 |
US20120237472A1 (en) * | 2009-07-24 | 2012-09-20 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2501800A4 (en) | 2009-11-17 | 2013-05-22 | Musc Found For Res Dev | HUMAN MONOCLONAL ANTIBODIES FOR HUMAN NUCLEOLIN |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
AU2011248540B2 (en) * | 2010-04-28 | 2014-11-20 | Oncolmmune, Inc. | Methods of use of soluble CD24 for therapy of rheumatoid arthritis |
CA2805465A1 (en) * | 2010-06-10 | 2011-12-15 | Myra Lipes | Diagnosis of myocardial autoimmunity in heart disease |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US20140075585A1 (en) * | 2012-09-12 | 2014-03-13 | Futwan Al-Mohanna | Tetraspanin CD82 as a Diagnostic and/or Therapeutic Module for Xenograft Recognition and/or Rejection |
HU230680B1 (hu) * | 2012-10-19 | 2017-08-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Diagnosztikai eljárás |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015028662A1 (en) * | 2013-08-30 | 2015-03-05 | Consejo Superior De Investigaciones Cientificas (Csic) | Compositions and methods for characterization and amelioration of rheumatoid arthritis |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US20160146799A1 (en) | 2014-11-05 | 2016-05-26 | Nirmidas Biotech, Inc. | Metal composites for enhanced imaging |
AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
CA3007419A1 (en) | 2015-12-30 | 2017-07-06 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
IT201700110784A1 (it) * | 2017-10-03 | 2019-04-03 | Fidia Farm Spa | Composizioni farmaceutiche contenenti Acido Ialuronico e Carnosina e relativo uso |
EP3520803A1 (en) * | 2018-01-31 | 2019-08-07 | Zarodex Therapeutics Limited | Novel uses |
WO2019168847A1 (en) | 2018-02-27 | 2019-09-06 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
EA202091710A1 (ru) | 2018-03-09 | 2021-02-16 | Агенус Инк. | Антитела против cd73 и способы их применения |
CN114470001A (zh) * | 2018-04-18 | 2022-05-13 | 浙江大学 | 人羊膜上皮细胞在自身免疫性疾病中的治疗用途 |
US11180547B2 (en) | 2018-05-08 | 2021-11-23 | Ten Peaks LLC | Methods for reducing drug-induced liver injury |
US10519227B2 (en) | 2018-05-08 | 2019-12-31 | Ten Peaks LLC | Methods for reducing drug-induced liver injury |
US11124566B2 (en) | 2018-05-08 | 2021-09-21 | Ten Peaks LLC | Methods for reducing drug-induced liver injury |
EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
KR20210049090A (ko) | 2018-07-05 | 2021-05-04 | 인사이트 코포레이션 | A2a/a2b 억제제로서 융합된 피라진 유도체 |
KR20210049871A (ko) | 2018-08-29 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 류마티스성 관절염을 갖는 대상체를 치료하기 위한 방법 및 조성물 |
WO2020054979A1 (ko) * | 2018-09-12 | 2020-03-19 | 아주대학교산학협력단 | Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물 |
RU2724469C2 (ru) | 2018-10-31 | 2020-06-23 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с cd20 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
KR20220057558A (ko) | 2019-09-06 | 2022-05-09 | 심포젠 에이/에스 | 항-cd73 항체 |
BR112022013236A2 (pt) | 2020-01-03 | 2022-09-06 | Incyte Corp | Anticorpos anti-cd73 e usos dos mesmos |
US12060433B2 (en) | 2020-01-03 | 2024-08-13 | Incyte Corporation | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy |
EP4014993A1 (en) * | 2020-12-21 | 2022-06-22 | Stichting Sint Maartenskliniek | Rituximab for treatment of polymyalgia rheumatica |
US20220233529A1 (en) | 2020-12-29 | 2022-07-28 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
CA2046909A1 (en) | 1989-03-21 | 1990-09-22 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
IL95125A (en) | 1989-07-19 | 1995-07-31 | Vandenbark Arthur Allen | T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
AU675916B2 (en) * | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
JP3571337B2 (ja) | 1992-02-11 | 2004-09-29 | セル ジェネシス,インコーポレーテッド | 遺伝子標的現象による同型遺伝子接合 |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
DE4225853A1 (de) * | 1992-08-05 | 1994-02-10 | Behringwerke Ag | Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
GB9413127D0 (en) | 1994-06-30 | 1994-08-24 | Philips Electronics Uk Ltd | Data processing apparatus |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
BR9509498A (pt) * | 1994-10-25 | 1997-12-23 | Glaxo Group Ltd | Agente aglutinante uso do mesmo composição farmacêutica e processo para tratamento de uma doença inflamatória autoimune ou uma doença alérgica |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5677189A (en) * | 1995-06-29 | 1997-10-14 | Oncomembrane, Inc. | Method for quantifying sphingosine and for diagnosing platelet activation |
AU716785B2 (en) | 1995-07-27 | 2000-03-09 | Genentech Inc. | Stabile isotonic lyophilized protein formulation |
DK0970207T3 (da) | 1997-02-10 | 2009-07-13 | Genentech Inc | Heregulin-varianter |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
AU740284B2 (en) | 1997-06-13 | 2001-11-01 | Genentech Inc. | Stabilized antibody formulation |
CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6368596B1 (en) * | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
CN1320044A (zh) | 1998-08-11 | 2001-10-31 | Idec药物公司 | 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法 |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
MY155913A (en) | 1998-11-09 | 2015-12-15 | Biogen Inc | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants |
ES2543819T3 (es) | 1998-11-09 | 2015-08-24 | Biogen Inc. | Tratamiento de neoplasias hematológicas asociadas con células tumorales circulantes utilizando anticuerpo quimérico dirigido contra CD20 |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
US6383276B1 (en) | 1999-03-12 | 2002-05-07 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
EP1642596A3 (en) * | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
DE60042785D1 (de) | 1999-06-09 | 2009-10-01 | Immunomedics Inc | Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
PL201086B1 (pl) | 1999-07-12 | 2009-03-31 | Genentech Inc | Zastosowanie przeciwciał wiążących się z antygenem CD20 |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
AU784971B2 (en) | 1999-08-11 | 2006-08-10 | Biogen Inc. | Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies |
JP2001058956A (ja) * | 1999-08-19 | 2001-03-06 | Welfide Corp | 自己免疫疾患予防・治療剤 |
AU6929100A (en) | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
AU2001264612C1 (en) | 1999-11-08 | 2007-11-22 | Biogen Idec Inc. | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
JP2003528155A (ja) | 2000-03-24 | 2003-09-24 | カイロン コーポレイション | Cd20に対する抗体とインターロイキン−2との組み合わせを用いる非ホジキンリンパ腫の治療方法 |
WO2001074388A1 (en) * | 2000-03-31 | 2001-10-11 | Idec Pharmaceuticals Corporation | Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma |
KR20020093029A (ko) | 2000-04-11 | 2002-12-12 | 제넨테크, 인크. | 다가 항체 및 그의 용도 |
AU5914201A (en) | 2000-04-25 | 2001-11-07 | Idec Pharma Corp | Intrathecal administration of rituximab for treatment of central nervous system lymphomas |
EP1299128A2 (en) * | 2000-06-20 | 2003-04-09 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
PT1296714E (pt) | 2000-06-22 | 2009-10-15 | Coley Pharm Gmbh | Combinação de cpg e anticorpos dirigidos contra cd19, cd20, cd22 ou cd40 para o tratamento ou prevenção do cancro |
US20020128448A1 (en) | 2000-10-20 | 2002-09-12 | Idec Pharmaceuticals Corporation | Variant IgG3 Rituxan and therapeutic use thereof |
MXPA03006771A (es) | 2001-01-29 | 2004-05-05 | Idec Pharma Corp | Anticuerpos modificados y metodos de uso. |
AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
EP2359849A1 (en) * | 2001-04-02 | 2011-08-24 | Genentech, Inc. | Combination therapy |
EP1404366A4 (en) | 2001-06-14 | 2006-06-07 | Intermune Inc | COMBINED THERAPY USING INTERFERON GAMMA AND SPECIFIC B-CELL ANTIBODIES |
WO2003029296A1 (en) | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
CN101914158A (zh) | 2002-02-14 | 2010-12-15 | 免疫医疗公司 | 抗cd 20抗体及其融合蛋白和使用方法 |
EP1532162B1 (en) | 2002-06-28 | 2013-08-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors |
BRPI0316779B1 (pt) * | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
JP2006522811A (ja) | 2003-04-09 | 2006-10-05 | ジェネンテック・インコーポレーテッド | TNFαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法 |
MY149159A (en) * | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
-
2004
- 2004-04-06 JP JP2006509724A patent/JP2006522811A/ja not_active Withdrawn
- 2004-04-06 PL PL04759142T patent/PL1613350T3/pl unknown
- 2004-04-06 AU AU2004229376A patent/AU2004229376B2/en not_active Expired
- 2004-04-06 KR KR1020057019095A patent/KR101092171B1/ko active IP Right Review Request
- 2004-04-06 PT PT04759142T patent/PT1613350E/pt unknown
- 2004-04-06 CN CNA2008101656563A patent/CN101371924A/zh active Pending
- 2004-04-06 UA UAA201006218A patent/UA99933C2/ru unknown
- 2004-04-06 CN CNA2004800161012A patent/CN1802176A/zh active Pending
- 2004-04-06 MX MXPA05010778A patent/MXPA05010778A/es active IP Right Grant
- 2004-04-06 CA CA002519870A patent/CA2519870A1/en not_active Withdrawn
- 2004-04-06 BR BRPI0409534-0A patent/BRPI0409534A/pt not_active Application Discontinuation
- 2004-04-06 DE DE602004020061T patent/DE602004020061D1/de not_active Expired - Lifetime
- 2004-04-06 WO PCT/US2004/010509 patent/WO2004091657A2/en active Application Filing
- 2004-04-06 RS YU20050761A patent/RS51686B/sr unknown
- 2004-04-06 ME MEP-2008-636A patent/ME00426B/me unknown
- 2004-04-06 ES ES04759142T patent/ES2322267T3/es not_active Expired - Lifetime
- 2004-04-06 EP EP04759142A patent/EP1613350B1/en not_active Revoked
- 2004-04-06 KR KR1020117008598A patent/KR20110044809A/ko not_active Application Discontinuation
- 2004-04-06 US US10/818,765 patent/US20040202658A1/en not_active Abandoned
- 2004-04-06 ZA ZA200507805A patent/ZA200507805B/en unknown
- 2004-04-06 DK DK04759142T patent/DK1613350T3/da active
- 2004-04-06 UA UAA200510467A patent/UA91961C2/ru unknown
- 2004-04-06 RU RU2005134394/14A patent/RU2358762C9/ru not_active IP Right Cessation
- 2004-04-06 EP EP09002405A patent/EP2062916A3/en not_active Withdrawn
- 2004-04-06 AT AT04759142T patent/ATE425766T1/de active
- 2004-04-06 SI SI200431115T patent/SI1613350T1/sl unknown
- 2004-04-06 NZ NZ587776A patent/NZ587776A/en unknown
-
2005
- 2005-09-22 IL IL171038A patent/IL171038A/en active IP Right Grant
- 2005-09-23 TN TNP2005000234A patent/TNSN05234A1/en unknown
- 2005-10-06 CR CR8033A patent/CR8033A/es not_active Application Discontinuation
- 2005-10-07 EC EC2005006082A patent/ECSP056082A/es unknown
- 2005-11-03 HR HR20050940A patent/HRP20050940A2/hr not_active Application Discontinuation
- 2005-11-08 NO NO20055253A patent/NO20055253L/no unknown
- 2005-11-09 MA MA28595A patent/MA27838A1/fr unknown
-
2006
- 2006-05-24 US US11/439,906 patent/US7708994B2/en active Active
- 2006-06-06 HK HK06106467.5A patent/HK1086480A1/xx not_active IP Right Cessation
-
2008
- 2008-03-20 US US12/052,606 patent/US7976838B2/en active Active
-
2009
- 2009-06-02 HR HR20090325T patent/HRP20090325T1/xx unknown
- 2009-06-04 CY CY20091100598T patent/CY1109127T1/el unknown
- 2009-10-01 NZ NZ580116A patent/NZ580116A/en unknown
- 2009-10-13 JP JP2009235927A patent/JP2010047586A/ja not_active Withdrawn
- 2009-12-29 IL IL203019A patent/IL203019A/en active IP Right Grant
-
2011
- 2011-05-16 US US13/108,134 patent/US20110300136A1/en not_active Abandoned
-
2013
- 2013-03-01 JP JP2013040359A patent/JP5746243B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1086480A1 (en) | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor | |
NO2018023I1 (pt) | ||
CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
UY28258A1 (es) | Tratamiento terapeutico | |
ATE461217T1 (de) | Glp-1-verbindungen | |
IL186616A (en) | Spyro-oxa-indoles and their use as drugs | |
IL146005A0 (en) | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers | |
IL180872A0 (en) | Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv | |
EP1753428A4 (en) | INHIBITORS OF KINASES AS THERAPEUTIC AGENTS | |
GB0419850D0 (en) | Therapeutic agents | |
TW200510398A (en) | Novel compounds | |
MXPA05011699A (es) | Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior. | |
GB0508988D0 (en) | Organic compounds | |
RS52038B (en) | USE OF 7-BUTOXYIMINOMETHYLAMPTOTECIN FOR THE TREATMENT OF NON-PLASMA NEOPLASMS | |
GB0400193D0 (en) | Therapeutic agents | |
ITTV20050186A1 (it) | Lettino per l'abbronzatura del corpo. | |
UA6623U (en) | Method for increasing therapeutic efficacy of clays | |
GB0400196D0 (en) | Therapeutic agents | |
TW200611700A (en) | New use of tetramethylpyrazine in the treatment of brain tumor | |
GB0402525D0 (en) | Therapeutic agents | |
GB0425207D0 (en) | Therapeutic agents | |
GB0427987D0 (en) | Therapeutic agents | |
GB0406432D0 (en) | Therapeutic agents | |
GB0408348D0 (en) | Therapeutic agents | |
GB0408100D0 (en) | Therapeutic agents |